Commentary

Interim Revision Announcements proposed in:
Pharmacopeial Forum 42(6) [Nov.–Dec. 2016]

March 31, 2017

In accordance with USP’s Rules and Procedures of the 2015-2020 Council of Experts ("Rules") and except as provided in Section 7.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be republished in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without republication in PF, a summary of comments received and the appropriate Expert Committee’s responses are published in the Revisions and Commentary section of the USP Web site at the time the official revision is published.

The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail.

For further information, contact:
USP Executive Secretariat
United States Pharmacopeia
12601 Twinbrook Parkway
Rockville, MD 20852-1790 USA
execsec@usp.org
Comments were received for the following IRAs, when they were proposed in Pharmacopeial Forum:

Monograph/Section: Topiramate/Multiple Sections
Expert Committee: Chemical Medicines Monographs 4
No. of Commenters: 1

Comment Summary #1: The commenter suggested that the detector temperature and column temperature should be the same in the tests for Assay and Organic Impurities.
Response: Comment not incorporated. The temperatures in the Assay and Organic Impurities sections are revised based on the inputs received from the sponsor.

Comment Summary #2: The commenter indicated that the resolution requirement is not necessary to determine the system suitability in the test for Assay.
Response: Comment not incorporated. The Expert Committee determined that the resolution between topiramate and topiramate related compound A is critical for establishing the system suitability.

Monograph/Sections: Almotriptan Malate/Limit of Almotriptan Related Compound D and Almotriptan N-Dimer
Expert Committee: Chemical Medicines Monographs 4
No. of Commenters: 1

Comment Summary #1: The commenter indicated that a range of migration times for 4-hydroxy-4-phenylpiperidine under Parameter Set B within Table 1 may not be suitable. When the voltage is adjusted so that 4-hydroxy-4-phenylpiperidine migrates within 12-15 minutes some systems do not function properly.
Response: Comment incorporated. The statements about the migration time of 4-hydroxy-4-phenylpiperidine were removed from Table 1.